Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia

Table 2 Comparison of EFS and OS between different clinical and molecular characteristic groups in ASXL1+ AML

Variables	OS		EFS
Variables	χ²	P-value	χ²	P-value
Sex (female vs. male)	0.69	0.406	0.719	0.395
Age (≥ 60 vs. < 60 years)	4.513	0.034	2.96	0.085
ASXL1 type (n [%])
G652S	0.911	0.34	1.528	0.216
G642fs	1.243	0.265	1.737	0.188
H630fs	0.592	0.442	0.214	0.643
ASXL1 VAF (≥ 49.17% vs. < 49.17%)	0.005	0.944	0.344	0.557
WBC counts (≥ 50 vs. < 50 × 10⁹/L)	4.471	0.035	7.564	0.006
HGB counts (≥ 110 vs. < 110 g/L)	0.131	0.717	0.085	0.77
PLT counts (≥ 100 vs. < 100 × 10⁹/L)	1.216	0.27	2.674	0.102
Bone marrow blasts (≥ 80% vs. < 80%)	0.611	0.434	0.364	0.546
Peripheral blasts (≥ 20% vs. < 20%)	1.242	0.537	1.939	0.379
Risk group (high-risk vs. low/inter)	7.719	0.005	8.231	0.004
Allo-HSCT (yes vs.no)	5.066	0.024	6.105	0.013
AML1-ETO (positive vs. negative)	6.583	0.01	6.229	0.013
CBFβ-MYH11 (positive vs. negative)	0	0.993	0.018	0.894
TET2 (mutated vs. wild type)	0.738	0.39	1.206	0.272
FLT3-ITD (positive vs. negative)	14.081	0	11.395	0.001
U2AF1 (mutated vs. wild type)	3.056	0.08	2.273	0.132
CEBPA (mutated vs. wild type)	0.954	0.329	0.476	0.49
NRAS (mutated vs. wild type)	1.338	0.247	0.986	0.321
DNMT3A (mutated vs. wild type)	1.824	0.177	1.205	0.272
IDH2 (mutated vs. wild type)	3.21	0.073	2.199	0.138
RUNX1 (mutated vs. wild type)	0.608	0.436	0.391	0.532
KIT (mutated vs. wild type)	1.557	0.212	1.949	0.163
SRSF2(mutated vs. wild type)	0.323	0.570	0.537	0.464

VAF variant allele frequency, WBC white blood cell, HGB hemoglobin, PLT platelet, allo-HSCT allogenic hematopoietic stem cell transplantation

ISSN: 1475-2867